Project to Accelerate New Treatments for Tuberculosis

What Project to Accelerate New Treatments for Tuberculosis does

Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is a non-profit, multi-stakeholder research collaboration launched in 2022 to develop simplified "pan-TB" drug regimens capable of treating both drug-sensitive and drug-resistant pulmonary tuberculosis without upfront drug-resistance testing. Its members — Evotec, GSK, Janssen Pharmaceutica NV (Johnson & Johnson), Otsuka Pharmaceutical, TB Alliance, the Bill & Melinda Gates Medical Research Institute (Gates MRI), and the Bill & Melinda Gates Foundation — have pooled registered products (bedaquiline, delamanid, pretomanid) and new chemical entities (quabodepistat, sutezolid, plus later additions such as sorfequiline, GSK-286, GSK-830, TBD09 and TBD11) under a Joint Development Agreement to advance two investigational regimens (DBQS and PBQS) through clinical evaluation.

The collaboration's core technology combines a wave-based nonclinical regimen-evaluation pipeline (combination pharmacokinetics, relapsing mouse model efficacy, and CFU-R/S ratio mouse model efficacy) with a multi-stage Phase 2b/c adaptive clinical trial design — initiated in August 2023 with the first participant screened in South Africa, with additional sites in the Philippines and Peru — that uses a Stop Treatment and Watch (STrAW) Concilium of blinded experts, video-observed therapy, medication reminder monitors, and a novel Biomarkers Strategy. All nonclinical data from 2020–2024 are standardized to the CDISC SEND format and made openly available to researchers via the Critical Path Institute's CP-DAP platform, creating an unusual degree of cross-sector data transparency for TB drug development.

PAN-TB has no commercial revenue model: it is funded by member cash, in-kind R&D contributions, drug assets, and scientific expertise, with the Gates MRI serving as sponsor of the Phase 2b/c trial. Its "customers" are effectively the global TB patient population and the health systems in high-burden countries (South Africa, Philippines, Peru, and beyond), and its outputs are distributed through the Gates-MRI-sponsored clinical trial network and the open CP-DAP data platform rather than via any product sale or pricing model.

Name

Project to Accelerate New Treatments for Tuberculosis

Legal name

Project to Accelerate New Treatments for Tuberculosis

Website

https://pan-tb.org

Company type

Private

Founded year

2022

Operating status

Operating

Short description

Non-profit multi-stakeholder collaboration (Evotec, GSK, Janssen, Otsuka, TB Alliance, Gates MRI, Gates Foundation) developing simplified, shorter pan-TB drug regimens and advancing them through Phase 2b/c trials and open nonclinical data sharing via the Critical Path Institute's CP-DAP platform.

Ownership category

akta.pro rank

Product category

Tuberculosis Drug Development Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Tuberculosis & Mycobacterial Diseases (HLAKAGAH)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Tuberculosis drug development
• Clinical trial collaboration
• Pan-TB regimens
• Nonprofit research partnership
• Translational TB science

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel

Revenue model

1. Philanthropic and member contributions: PAN-TB is a non-profit, multi-stakeholder R&D collaboration rather than a revenue-generating commercial entity. It is funded and resourced by its members — philanthropic (Bill & Melinda Gates Foundation), non-profit (TB Alliance, Gates MRI), and private-sector (Evotec, GSK, Otsuka, Janssen) — who contribute cash, in-kind R&D, drug assets, and scientific expertise. The Phase 2b/c trial is sponsored by Gates MRI. There is no commercial pricing or product sale.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

PAN-TB is a non-profit, multi-stakeholder research collaboration that discovers and develops simplified pan-TB treatment regimens by combining registered anti-TB drugs and new chemical entities (bedaquiline, delamanid, pretomanid, quabodepistat, sutezolid) and advancing them through wave-based nonclinical evaluation and an adaptive two-stage Phase 2b/c clinical trial in high-burden countries (South Africa, Philippines, Peru). The program's lead output is two investigational regimens, DBQS and PBQS, designed to be shorter (target 2–4 months), simpler, and active against both drug-sensitive and drug-resistant TB.

Differentiator

Problem solved

Functional benefit

Products and services

• DBQS regimen (delamanid, bedaquiline, quabodepistat, sutezolid)
• PBQS regimen (pretomanid, bedaquiline, quabodepistat, sutezolid)
• Phase 2b/c clinical trial (DBQS vs. PBQS vs. standard of care)
• PAN-TB nonclinical data package on Critical Path Institute CP-DAP

Quantifiable outcome

• Target pan-TB regimen duration of 2–4 months (vs. current 6+ month standard of care)
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IAVI (International AIDS Vaccine Initiative): Global non-profit R&D organization developing vaccines and antibodies, including TB vaccines. Comparable as a multi-stakeholder product development partnership in the broader infectious-disease space with overlapping global-health funders.
• Medicines for Malaria Venture (MMV): Established non-profit product development partnership for malaria drug regimens — operates the same public-private R&D collaboration model as PAN-TB in an adjacent infectious-disease vertical. Useful comparable for non-commercial drug development governance and access strategies.

Emerging players

• UNITE4TB (IMI): European-led public-private partnership running Phase 2b/c clinical trials of new TB regimens in high-burden countries. Operates an overlapping trial footprint with PAN-TB and is coordinated with the collaboration on regimen development.
• ERA4TB (IMI): European Accelerate Research and Development for Tuberculosis — an IMI-backed consortium focused on early-stage TB drug regimen discovery. Directly comparable as a multi-stakeholder TB R&D consortium, though earlier-stage than PAN-TB.
• Foundation for Innovative New Diagnostics (FIND): Non-profit advancing diagnostic solutions for TB and other poverty-related diseases. Comparable as a global-health product development partner focused on TB, though focused on diagnostics rather than regimens.

Direct peers

• TB Alliance (Global Alliance for TB Drug Development): Non-profit product development partnership advancing new TB regimens; PAN-TB member and owner of pretomanid and sutezolid. Most directly comparable as a non-profit TB drug R&D organization pursuing shorter, simpler regimens.
• TB Drug Accelerator (TBDA): Multi-stakeholder consortium pooling resources from pharma, academia, and government to discover and develop new TB drug regimens. PAN-TB explicitly coordinates with TBDA to avoid duplication and share data, making it a directly comparable consortium structure.
• Bill & Melinda Gates Medical Research Institute (Gates MRI): Non-profit R&D organization sponsoring the PAN-TB Phase 2b/c trial and developing new interventions for TB, malaria, and diarrheal diseases. Functions as both a PAN-TB member and a translational R&D peer.
• Drugs for Neglected Diseases initiative (DNDi): Non-profit product development partnership advancing new treatments for neglected diseases including TB. Operates the same multi-stakeholder, non-commercial R&D model as PAN-TB and is a clear structural peer.

Others

• Working Group on New TB Drugs (WHO Stop TB Partnership): WHO-affiliated coordination body for global TB drug R&D stakeholders; PAN-TB participates in adjacent consortia that overlap with this working group's mission of advancing new TB regimens through coordinated R&D.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Project to Accelerate New Treatments for Tuberculosis